Products and Resources Catalog

The Naloxone is an Act of Love website was developed with support by the New England Addiction Technology Transfer Center (ATTC) in partnership with the Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose. The website hosts a suite of resources designed to reduce stigma surrounding the use of naloxone and those who experience an opioid overdose along with encouraging viewers to get trained in and carry Naloxone. Specific resources include narrative videos, posters, and coasters. 

This snapshot is intended to bring awareness to individuals, families, professionals, and providers about the serious substance use disorder problem among the Hispanic and Latino Veteran population. Español LOS VETERANOS Y LOS TRASTORNOS EN CONSUMO DE SUSTANCIAS Esta reseña infomativa tiene como objetivo proporcionar recursos a individuos, padres, profesionales y proveedores sobre el grave problema del trastorno por uso de sustancias en la población de Veteranos Hispanos y Latinos Português VETERANOS HISPÂNICOS E LATINOS E TRANSTORNOS POR USO DE SUBSTÂNCIAS (TUS) Esta síntese de informações destina-se a fornecer recursos para indivíduos, familiares, profissionais e provedores sobre o grave problema de transtorno por uso de substâncias entre a população hispânica e latina veterana.

The July 2022 Dialogue contains articles on: Addiction: Construction Work and Opioids | Mental Health: Mental Health in the BIPOC Community | Prevention: BIPOC Mental Health Month | ORN: Diversity, Equity, and Inclusion. Additional sections include behavioral health observances, virtual training and webinar events, Region 3 news, new resources, and Regional Spotlight: PPW Addiction Treatment Center – Claymont Center for Pregnant & Parenting Women. Additional sections include upcoming training and webinar events, behavioral health observances, new resources, and Region 3 news. The Dialogue is designed to inform behavioral and mental health professionals of news and upcoming events in the Central East states. This electronic newsletter is disseminated bi-monthly on the first Tuesday. You are encouraged to provide us with any feedback or submit articles and topics for discussion in future issues of the newsletter, [email protected]. Sign up to receive the Dialogue in your mailbox. Visit the Dialogue Archives.

This webinar, presented by Gail D'Onofrio, MD, focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. The opioid epidemic combined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with rising rates of fentanyl use. Dr. D'Onofrio shared data supporting the use of buprenorphine in the ED and discussed the consequences of not initiating treatment, barriers to implementation of ED buprenorphine, and components of successful integration of an ED program with community partnerships. She also shared current research by emergency physicians regarding innovative strategies like high-dose induction and use of an extended release 7-day formulation of buprenorphine. Sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network. Download slides | Watch recording

Harm reduction is any action that reduces risk and increases personal and public safety. Harm reduction approaches have proven to prevent death, injury, disease, overdose, prevent substance misuse or disorder and most of us practice harm reduction techniques daily. For example, when we wear a seatbelt or apply sunscreen we are using harm reduction strategies.  Fentanyl strips, naloxone, and needle exchange programs are also examples of harm reduction.  This poster identifies some of the most common harm reduction methods in an attempt to normalize the term "harm reduction" and broaden the definition.   The Spanish translations were prepared by consultants for the Mountain Plains ATTC. While reasonable efforts are made to provide accurate translations, acknowledging the diversity of Spanish and English Language, some words/phrases may differ.   The poster can be downloaded in multiple formats directly from the MPATTC website. This product was designed for display as an 11x17 sized poster in a location most visible and accessible to behavioral health providers, educators, and/or peer recovery specialists but is also available in an 8.5x11 format for in-house printing. In addition, hard copies may be requested from the MPATTC by emailing us at [email protected] (posters can be mailed within the continental United States). Please click on the link below for more information.   To request an 11x17 "What is Harm Reduction?" poster to be mailed directly to you, please click "REQUEST A HARD COPY".  

Fatal overdoses are skyrocketing, and rates of substance use remain high, demonstrating the need to expand substance use disorder (SUD) treatment. In 2020, fatal overdoses in the Central East increased 25% (from 9,909 to 12,377), with overdose rates above the national average in every state except Virginia. Rates of substance use and SUD are persistently elevated. Funding additional treatment services and expanding access to existing treatment can help address the problem. This factsheet provides statistics and justifications for increasing SUD treatment.

The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.   Alcohol is STILL a Drug: An Exploratory Webinar Series (May 3, 2022) Recording     DESCRIPTION  Alcohol is STILL a drug.  The opioid crisis, increase in stimulant misuse, and marijuana legalization dominate the news— yet alcohol remains the number one substance causing health, social, legal and financial problems throughout the US. While this series will focus on the hopefulness of recovery from alcohol use disorder, we’ll also take a deep dive into what we know about the full impact of alcohol overuse and the ways it affects every person in the US.     SPEAKER Gabriela Zapata-Alma, LCSW, CADC Gabriela Zapata-Alma, LCSW, CADC, is the Associate Director at the National Center on Domestic Violence, Trauma, and Mental Health, as well as a lecturer at the University of Chicago, where they direct the Alcohol and Other Drug Counselor Training Program. Gabriela brings over 15 years of experience supporting people impacted by structural and interpersonal violence and their traumatic effects through evidence-based clinical, housing, resource advocacy, and HIV-specific integrated care programs. Currently, Gabriela authors best practices, leads national capacity-building efforts, and provides trauma-informed policy consultation to advance health equity and social justice.     SERIES LEARNING OBJECTIVES These are the overall learning objectives for the full 10-session series:  Summarize the current impacts of problematic alcohol use in various/special populations, including pregnant women, youth, rural, and minority populations.  Assess and prioritize alcohol reduction efforts in targeted settings.  Describe the current efforts to curb problematic alcohol use, including best practices in providing treatment. 

Alcohol is STILL a Drug: An Exploratory Webinar Series: March 1, 2022, Recording   The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.     DESCRIPTION  Alcohol is STILL a drug.  The opioid crisis, increase in stimulant misuse, and marijuana legalization dominate the news— yet alcohol remains the number one substance causing health, social, legal and financial problems throughout the US.    While this series will focus on the hopefulness of recovery from alcohol use disorder, we’ll also take a deep dive into what we know about the full impact of alcohol overuse and the ways it affects every person in the US.   This session will provide an introduction to Fetal Alcohol Spectrum Disorders (FASD) including general information about the risks of alcohol intake during pregnancy, the negative impact on the developing fetus, as well as how to prevent it.     SERIES LEARNING OBJECTIVES These are the overall learning objectives for the full 10-session series:  Summarize the current impacts of problematic alcohol use in various/special populations, including pregnant women, youth, rural, and minority populations.  Assess and prioritize alcohol reduction efforts in targeted settings.  Describe the current efforts to curb problematic alcohol use, including best practices in providing treatment.        TRAINER     Lisa Rahm, BS, CMP Lisa Rahm is the Special Initiatives Manager for Prevention First. She has 28 years of experience in the education and human services fields with the last 21 years at Prevention First. In her current position, she has developed, implemented, and evaluated special initiatives such as FASD Screening and Brief Intervention Project, and Statewide FASD Project as well as overseeing conferences, meeting planning, and special events. Rahm holds a Bachelor of Science in Organizational Leadership from Greenville College and holds the certification as a Certified Meeting Professional (CMP).

The New England ATTC co-hosted the Recovery Science and Harm Reduction (RSHR) Reading Group meeting on February 24, 2022 from 12:30 PM to 1:30 PM. This discussion reviewed the article, “Patient Perspectives on Choosing Buprenorphine Over Methadone in an Urban, Equal-Access System.”  View the February 2022 RSHR Reading group meeting summary that includes a brief article summary and key themes that arose in discussion with the participants.

The November 2021 Dialogue contains articles on: Addiction: Native Americans & the Opioid Crisis | Mental Health: Spread Kindness | Prevention: Veterans and Substance Use Prevention | ORN: Mobile Clinics Reach Rural Areas | Spotlight: Dr. Ala Stanford Center for Health Equity (ASHE). Additional sections include upcoming training and webinar events, behavioral health observances, new resources, and Region 3 news. The Dialogue is designed to inform behavioral and mental health professionals of news and upcoming events in the Central East states. This electronic newsletter is disseminated bi-monthly on the first Tuesday. You are encouraged to provide us with any feedback or submit articles and topics for discussion in future issues of the newsletter, [email protected]. Sign up to receive the Dialogue in your mailbox. Visit the Dialogue Archives.

The New England ATTC co-hosted the Recovery Science and Harm Reduction (RSHR) Reading Group meeting on August 19, 2021 from 12:30 PM to 1:30 PM. This discussion reviewed the article, “"It’s not just injecting drugs”: Supervised consumption sites and the social determinants of health.”  View the August 2021 RSHR Reading group meeting summary that includes a brief article summary and key themes that arose in discussion with the participants.

These Telehealth MOUD Video Demonstrations show distinct clinical interactions common across the medications for opioid use disorder (MOUD) modality. Except for the first two videos listed (Buprenorphine Induction and Re-induction to Buprenorphine), which show the same mock patient at two stages along his treatment trajectory, the videos in this collection are independent depictions showcasing different settings, patient situations, and provider types. The common thread for these videos is that each patient portrayed has an opioid use disorder and is considering or engaged in medication treatment. This set of videos may be useful for individuals entering the MOUD workforce or for MOUD patients and family members curious about what happens at various points in treatment.  Produced by the Northwest ATTC (SAMHSA grant no. TI080201), in co-sponsorship with Southeast ATTC (SAMHSA grant no. TI080215) and the ATTC Network Coordinating Office (SAMHSA grant no. TI080205). We thank the clinicians involved for their conceptual contributions to the development of these characters and the clinical scenario.

This month our National Hispanic and Latino ATTC and PTTC would like to support August’s Overdose Awareness Month and International Overdose Awareness Day, which takes place annually on August 31st.   Resources: https://salud-america.org/drug-overdose-deaths-during-covid-19-a-historical-spike-among-latinos/    www.overdoseday.com #NLBHA #NHLATTC #NHLPTTC Español  Nuestros Centros Nacionales Hispano y Latino ATTC y PTTC desean apoyar el Mes de Concientización de Sobredosis de el mes de agosto y el Día Internacional de Concientización de Sobredosis, que tiene lugar anualmente el 31 de agosto.   Recursos: https://salud-america.org/drug-overdose-deaths-during-covid-19-a-historical-spike-among-latinos/    www.overdoseday.com #NLBHA #NHLATTC #NHLPTTC Português Neste mês, nós gostaríamos de apoiar o Mês de Conscientização sobre a Overdose e o Dia Internacional de Conscientização sobre a Overdose, que ocorre anualmente em 31 de agosto.   Recursos: https://salud-america.org/drug-overdose-deaths-during-covid-19-a-historical-spike-among-latinos/    www.overdoseday.com #NLBHA #NHLATTC #NHLPTTC

Presenter: Jenna van Draanen, PhD, MPH, University of Washington July 2021 This one-hour webinar discussed the role of harm reduction in addiction treatment and how it fits with other systems of care. In addition to covering recent service use patterns in the Northwest, Dr. van Draanen shared evidence and lessons learned from her work with overdose prevention sites (a model of peer-run safe consumption sites) in Vancouver, Canada. The session covered changes in overdose prevention site utilization during COVID-19, the importance of peer involvement in service delivery, and outcomes associated with overdose prevention site utilization. Download slides

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes, Talking to Change: An MI Podcast. Episode 42: MI for People with Opioid Use and Stimulant Use Disorders, with Roy Stein, MD In this episode (the first of two episodes about MI for opioid and stimulant use disorders), Glenn and Sebastian talk to Dr. Roy Stein, Clinical Professor of Psychiatry at University of North Carolina’s School of Medicine. Dr. Stein talks about ways to help people engaging in behavior that puts them at high risk for death, managing the “righting reflex” and reducing risk for burnout, the role of harm reduction for opioid use disorders, adaptations of MI for stimulant use disorders, medication treatment for substance use disorders, and more. Download transcript (pdf)

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes. Talking to Change: An MI Podcast. Episode 44: MI and Social Support for Opioid and Stimulant Use Disorders, with Paul Delaney In part two of a pair of episodes on MI for opioid and stimulant use disorders, Glenn and Sebastian talked to Paul Delaney, clinical supervisor, therapist, adult educationalist, and trainer in Dublin, Ireland. Paul talked about working with people who misuse opioids and stimulants, how to avoid the premature focus trap, ways to support autonomy with someone who uses heroin, harm reduction, and MI and restorative justice.  Download the transcript (pdf)  

This training focuses on reducing personal, public, and institutionalized biases around people with substance use disorder. We will learn details of drug use, overdose, and navigating the care continuum by someone with lived experience who is now a Peer Recovery Support Specialist in Kansas City, MO. We will look at this story and the role bias played in delaying and distressing the recovery process. Participants learn about types of stigma, addiction on the brain, and evidence-based practices in overdose response. There will be multiple opportunities to observe how bias affects their own experiences and to discuss ways to shift attitudes and improve actions which lead to better outcomes and more people in recovery. Click here to watch the presentation!

This is the final session of the 3-part series Embracing Pregnant & Parenting Families Challenged with Substance Use Disorder. After the session, participants will be able to: Recognize data relevant to addiction and recovery in the United States Define stigma and examine its impact upon individuals experiencing addiction and those in recovery Discuss implicit bias and examine strategies to examine and reduce our own unconscious bias Illustrate the power of language in relationship to stigma and contrast stigmatizing language with the language of recovery Identify actions each member of the health care team can take to reduce the impact of stigma Click here to watch the presentation Presenter Information: Sharon Hesseltine, BSW, is President and CEO of Intentional Development, providing consultation, facilitation and training to strengthen services for pregnant and parenting families who have substance use disorders, adverse childhood experiences (ACEs) and trauma. For over 30 years Sharon has worked in Public Health and specialized in early childhood development, women’s health, substance use disorder and recovery.  

In this session, Larissa Mooney, MD, one of two PIs for the Greater Southern California Node of the NIDA Clinical Trials Network, discussed recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants also learned about the treatment approaches to address this rising comorbidity. This webinar was sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network. Download slides

  Participants in this webinar will be able to name ways addiction impacts the maternal and infant brain, identify prevention strategies, describe the significance of attachment parenting to promote infant resilience, and discuss the risk of inherited genetics. 

  Participants in this webinar will be able to name two brain systems impacted by exposure to adverse childhood experiences, describe three social, emotional, and behavioral impacts of exposure to ACEs during adolescence, and identify stigma in self and in others. 

This three-part series will focus on the principles of harm reduction and its strategies to advance holistic services for individuals with substance use disorder (SUDs). Research indicates that harm reduction programs are evidence-based public health strategies designed to prevent overdose deaths, infectious disease, sexually transmitted infections, pregnancies, and injection drug use. For example, expanding access to naloxone for individuals using opioids is considered a harm reduction strategy. Specifically, this webinar series will include: an overview of the principles of harm reduction and their application in a harm reduction center; the importance of engaging law enforcement especially in rural areas and co-responder models; and a panel of experts discussing their expertise in offering harm reduction strategies in their service delivery as well as a consumer of harm reduction services.   Session One March 30, 2021, from noon to 1:00 MT, will feature Lisa Raville, Executive Director of the Harm Reduction Action Center in Denver, CO. Ms. Raville will provide an overview of the principles of harm reduction.   The learning objectives include: -An examination of the principles and evidence for the application of harm reduction strategies. -The role of harm reduction programs in eliminating stigma and shame. -Strategies to work cross-systems to advance harm reduction. -Data from a recent survey of healthcare workers.   Video Link Session Two April 13, 2021, from noon to 1:00 MT, will feature Chief Rick Brandt, Chief of Police in Evans, CO. Chief Brandt will provide content specific to engagement with law enforcement in harm reduction to include:  -Strategies to educate law enforcement on harm reduction in rural communities. -Content on how to implement harm reduction in a PD and the leadership strategies employed. -The role of law enforcement in working cross-system to prevent overdose deaths. -Application of co-responder models. Video Link   Session Three April 27, 2021, from noon to 1:30 MT, will feature a panel discussion to include the following panelists: (1) Lisa Raville, Executive Director of the Harm Reduction Action Center in CO, (2) Chris Harsell, ATTC Technical Trainer and Medical Director for Spectra Health in ND, (3) Gabriela Zapata-Alma, Director of Policy and Practice on Domestic Violence and Substance Use for the National Center on Domestic Violence, Trauma, and Mental Health in Chicago, Il, (4) and a consumer of harm reduction services. The focus will be on: -Responding to questions surrounding implementation strategies. -Community and consumer benefits of harm reduction services. -How harm reduction can be employed in any agency. Video Link

The Kansas City Perinatal Recovery Collaborative (KCPRC) was formed in June 2018 by Mid-America ATTC in response to the growing impact of substance use on families in the bi-state metropolitan area.  The KCPRC works to develop, grow, and nurture a coordinated, multi-system network of services and programs to support pregnant and parenting mothers as they navigate the dual journey of parenting and recovery. KCPRC is a collective of professionals from child development, child welfare, housing, social services, health care, criminal justice, and substance use disorder treatment and recovery.  The group focuses on evidence-based ways care can be improved from pregnancy and throughout a woman’s continuum of care. 

BHMEDS-R3 App The BHMEDS-R3 app is designed as a quick reference for non-prescriber behavioral health professionals and consumers who need general knowledge about medications prescribed for behavioral health conditions. The language has been modified to increase readability for a larger audience and, in keeping with the goal of continuously updating the app content, new medications are added after FDA approval. Download the FREE app using the QR codes below. Use the BHMEDS-R3 app for the following: Browse through different types of behavioral health medications Click a medication category icon to learn more details, including brand and generic names Use drop-down navigation menus to learn more about medications’ purpose, dose and frequency, side effects, emergency conditions, misuse potential, and cautions. Access provider tools and other free medication resources   BHMEDS-R3 Behavioral Health Medications Originally developed as a companion piece to the Mid-America ATTC curriculum, A Collaborative Response: Addressing the Needs of Consumers with Co-Occurring Substance Use and Mental Health Disorders (2000), this publication is now available as a downloadable PDF and replicates the content included in the new BHMEDS-R3 app now available in the Apple App Store and Google Play.  Back by popular demand, this 10th Edition publication is acclaimed for its accessibility as an educational reference for addiction professionals, patients, and families. Educators and addiction counselor training programs across the United States have asked that we continue to update and publish a downloadable publication to reflect the same credible and up-to-date information included in the BHMEDS-R3 app. We attempt to update the BHMEDS-R3 app content annually and publish an updated publication biannually.    Medications are organized in 11 sections: Alcohol Use Disorder Treatment Antianxiety Medications Antidepressant Medications Antimanic/Mood Stabilizer Medications Antipsychotics/Neuroleptics Hypnotics (Sleep Aids) Medications Induced Symptoms Treatment Narcotic and Opioid Medications Opioid Use Disorder Treatment Stimulant Medications Tobacco   Each section includes the following topics for the different medication types: Generic and Brand Name Medications: includes both approved FDA approved and “off label” medications.  Purpose: Describes typical uses of medications, including specific symptoms treated and positive treatment response expected.  Dose & Frequency: Discusses when and how medications are administered.  Side Effects: Discusses potential side effects, and methods for monitoring side effects.  Emergency Conditions: Includes risks associated with overdose, withdrawal or other medications’ reactions. Misuse Potential: Elaborates upon those medications with risk factors related to misuse and/or development of physical dependence.  Cautions: Describes general guidance on risks associated with taking medications    IMPORTANT NOTES ACROSS MEDICATION TYPES Name brand medications have a limited patent. When the patent expires, the medication may be made as a generic. The generic name of a medication is the actual name of the medication and never changes. A generic medication may be made by many different manufacturers and can make several forms of a single medication with only slight variations in color, size, or shape.